Heron Therapeutics, Inc

(NASDAQ:HRTX)

Latest On Heron Therapeutics, Inc (HRTX):

Date/Time Type Description Signal Details
2023-05-13 00:29 ESTNewsHeron stock slumps ~35% amid quarterly misses on both linesN/A
2023-05-12 10:15 ESTNewsHeron Therapeutics, Inc. (HRTX) Q1 2023 Earnings Call TranscriptN/A
2023-05-11 20:40 ESTNewsHeron Therapeutics GAAP EPS of -$0.27 misses by $0.07, revenue of $29.62M misses by $0.07MN/A
2023-05-11 05:36 ESTNewsHeron Therapeutics Q1 2023 Earnings PreviewN/A
2023-04-21 21:15 ESTNewsCleaning The House May Not Solve Heron Therapeutics' ProblemsN/A
2023-04-03 22:18 ESTNewsHeron Therapeutics picks industry veteran as CEO, elects new board chairmanN/A
2023-03-24 11:39 ESTNewsHeron Therapeutics, Inc. 2022 Q4 - Results - Earnings Call PresentationN/A
2023-03-24 11:39 ESTNewsHeron Therapeutics, Inc. (HRTX) Q4 2022 Earnings Call TranscriptN/A
2023-03-24 11:38 ESTNewsHeron stock falls ~10% as headwinds for Zynrelef label, device delivery lingerN/A
2023-03-23 20:00 ESTNewsHeron Therapeutics GAAP EPS of -$0.17 beats by $0.15, revenue of $30.03M beats by $2.79MN/A
2023-03-23 03:36 ESTNewsHeron Therapeutics Q4 2022 Earnings PreviewN/A
2023-03-07 20:17 ESTNewsHeron Therapeutics (HRTX) presents at 2023 Cowen Conference - SlideshowN/A
2023-02-22 13:47 ESTNewsHeron gains on agreement with Rubric Capital and Velan CapitalN/A
2023-02-06 18:36 ESTNewsHeron climbs 14% as Rubric Capital discloses ~10% stakeN/A
2022-12-29 18:57 ESTNewsHeron spikes on FDA filing to expand label for pain therapyN/A
2022-12-20 13:03 ESTNewsHeron Therapeutics: Struggling Unsuccessfully With Its Slate Of Approved ProductsN/A
2022-11-09 06:53 ESTNewsHeron Therapeutics reports Q3 results, affirms FY oncology care franchise revenue guidanceN/A
2022-11-09 06:53 ESTNewsHeron Therapeutics, Inc. (HRTX) Q3 2022 Earnings Call TranscriptN/A
2022-11-07 19:56 ESTNewsHeron Therapeutics Q3 2022 Earnings PreviewN/A
2022-09-20 17:29 ESTNewsHeron Therapeutics Is Not Out Of The Woods YetN/A
2022-09-17 04:36 ESTNewsHeron wins FDA nod for post-operative agent to address nausea and vomitingN/A
2022-08-10 01:17 ESTNewsHeron Therapeutics GAAP EPS of -$0.55 misses by $0.05, revenue of $27.63M beats by $2.98MN/A
2022-08-10 01:16 ESTNewsHeron Therapeutics to raise $76.5M in stock and warrants offeringN/A
2022-08-10 01:16 ESTNewsHeron Therapeutics, Inc. 2022 Q2 - Results - Earnings Call PresentationN/A
2022-08-10 01:16 ESTNewsHeron Therapeutics rises 16% on Q2 revenue beat, raises 2022 sales forecastN/A
2022-08-10 01:16 ESTNewsHeron Therapeutics, Inc.'s (HRTX) CEO Barry Quart on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-09 03:30 ESTNewsHeron Therapeutics Q2 2022 Earnings PreviewN/A
2022-06-30 11:35 ESTNewsHeron Therapeutics proposes 34% cut in workforce as part of cost reduction planN/A
2022-05-10 06:55 ESTNewsHeron Therapeutics GAAP EPS of -$0.63 misses by $0.15, revenue of $23.46M beats by $0.85MN/A
2022-05-10 06:54 ESTNewsHeron Therapeutics, Inc. (HRTX) CEO Barry Quart on Q1 2022 Results - Earnings Call TranscriptN/A
2022-04-13 18:27 ESTNewsHeron Therapeutics (HRTX) Presents At 21st Annual Needham Virtual Healthcare Conference - SlideshowN/A
2022-04-01 07:21 ESTNewsHeron Therapeutics: Cash Is A Problem AgainN/A
2022-03-17 11:23 ESTNewsHeron Therapeutics wins Health Canada approval of Zynrelef for postoperative painN/A
2022-03-05 00:01 ESTNewsHeron Therapeutics, Inc. 2021 Q4 - Results - Earnings Call PresentationN/A
2022-03-03 12:39 ESTNewsHeron Therapeutics: Changing Strategy After Disappointing EarningsN/A
2022-03-02 01:58 ESTNewsHeron stock falls 21% as Q4 sales remain largely flat Y/YN/A
2022-03-01 07:42 ESTNewsHeron Therapeutics GAAP EPS of -$0.54 beats by $0.04, revenue of $20.66M misses by $5.11MN/A
2022-03-01 07:42 ESTNewsHeron Therapeutics, Inc. (HRTX) CEO Barry Quart on Q4 2021 Results - Earnings Call TranscriptN/A
2022-02-28 11:50 ESTNewsHeron Therapeutics Q4 2021 Earnings PreviewN/A
2021-11-18 16:27 ESTNewsHeron Therapeutics submits HTX-019 application to FDA for prevention of PONVN/A
2021-11-04 10:25 ESTNewsHeron Therapeutics EPS beats by $0.10, misses on revenueN/A
2021-11-04 10:25 ESTNewsHeron Therapeutics, Inc. (HRTX) CEO Barry Quart on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-03 13:24 ESTNewsHeron Therapeutics Q3 2021 Earnings PreviewN/A
2021-10-07 12:17 ESTNewsHeron Therapeutics: Looking For Signs Of The BottomN/A
2021-08-09 08:57 ESTNewsHeron Therapeutics EPS misses by $0.06, misses on revenueN/A
2021-07-23 00:53 ESTNewsHeron Therapeutics highlights promising data from ZYNRELEF postoperative pain trialsN/A
2021-07-21 11:40 ESTNewsHeron Therapeutics completes $150 million convertible debt financingN/A
2021-07-21 11:35 ESTNewsHeron Therapeutics files for 12.4M common stock offering from shareholderN/A
2021-07-21 11:15 ESTNewsHeron Therapeutics launches ZYNRELEF in the U.S.N/A
2021-04-04 15:43 ESTNewsMost-shorted U.S. stocks fall after rise earlier this year on GameStop squeezeN/A

About Heron Therapeutics, Inc (HRTX):

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam, which is in Phase III clinical trials for pain management; and HTX-034, which is in Phase Ib/II clinical trials for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

HRTX Quotes by TradingView

See Advanced Chart

General

  • Name Heron Therapeutics, Inc
  • Symbol HRTX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 223
  • Last Split Factor1:20
  • Last Split Date2014-01-13
  • Fiscal Year EndDecember
  • IPO Date1987-08-26
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.herontx.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 16.77
  • Price/Book (Most Recent Quarter) 6.33
  • Enterprise Value Revenue 14.82
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.07
  • Next Year EPS Estimate -$1.08
  • Next Quarter EPS Estimate -$0.54
  • Profit Margin -256%
  • Operating Margin -251%
  • Return on Assets -32%
  • Return on Equity -71%
  • Revenue 88.64 million
  • Earnings Per Share -$2.56
  • Revenue Per Share $0.98
  • Gross Profit -120884000
  • Quarterly Earnings Growth -41.3%
View More

Highlights

  • Market Capitalization 1.43 billion
  • EBITDA -205512000
  • PEG Ratio -0.18
  • Analyst Target Price $34
  • Book Value Per Share $2.59
View More

Share Statistics

  • Shares Outstanding 91.4 million
  • Shares Float 79.79 million
  • % Held by Insiders 29%
  • % Held by Institutions 101.43%
  • Shares Short 20.15 million
  • Shares Short Prior Month 19.71 million
  • Short Ratio 21.47
  • Short % of Float 27%
  • Short % of Shares Outstanding 22%
View More

Technicals

  • Beta 1.45
  • 52 Week High $22.4
  • 52 Week Low $10.74
  • 50 Day Moving Average 18.15
  • 200 Day Moving Average 17.33
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Heron Therapeutics, Inc (HRTX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Heron Therapeutics, Inc (HRTX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-24$N/A-$0.68-$0.63-7.94%
2020-09-302020-11-05$N/A-$0.64-$0.62-3.56%
2020-06-302020-08-05$N/A-$0.61-$0.60-1.67%
2020-03-312020-05-06$N/A-$0.57-$0.6715.18%
2019-12-312020-03-02$35.08 million-$0.65-$0.56-15.72%
2019-09-302019-11-12$42.62 million-$0.42-$0.5827.8%
2019-06-302019-08-05$36.66 million-$0.63-$0.62-1.07%
2019-03-312019-05-09$31.6 million-$0.80-$0.50-61.39%
2018-12-312019-02-22$28.84 million-$0.63-$0.47-32.83%
2018-09-302018-11-07$19.79 million-$0.49-$0.44-11.72%
2018-06-302018-08-08$17.28 million-$0.54-$0.6820.08%
2018-03-312018-05-10$11.57 million-$0.81-$0.887.61%
2017-12-312018-02-27$10.05 million-$1.09-$0.79-37.97%
2017-09-302017-11-06$8.57 million-$0.77-$0.8610.78%
2017-06-302017-08-09$8.51 million-$0.80-$0.9111.81%
2017-03-312017-05-10$3.63 million-$1.00-$0.95-5.11%
2016-12-312017-02-23$1.28 million-$1.22-$1.230.7%
2016-09-302016-11-08$N/A-$1.24-$1.21-2.12%
2016-06-302016-08-08$N/A-$1.17-$0.96-21.88%
2016-03-312016-05-05$N/A-$0.92-$0.87-5.26%
2015-12-312016-02-19$N/A-$0.87-$0.66-31.48%
2015-09-302015-11-06$N/A-$0.63-$0.675.97%
2015-06-302015-08-07$N/A-$0.74-$0.65-13.85%
2015-03-312015-05-08$N/A-$0.70-$0.68-2.94%
2014-12-312015-03-13$N/A-$0.71-$0.7910.13%
2014-09-302014-11-06$N/A-$0.66-$0.7714.29%
2014-06-302014-08-04$N/A-$0.78-$0.74-5.41%
2014-03-312014-05-08$N/A-$0.74-$0.67-10.45%
2013-12-312014-03-05$N/A-$0.75-$0.53-41.51%
2013-09-302013-11-12$N/A-$0.80-$0.9313.98%
2013-06-302013-08-08$N/A-$1.00-$0.80-25%
2013-03-312013-05-10$N/A-$0.80-$0.60-33.33%
2012-12-312013-03-01$-599000-$0.60-$0.40-50%
2012-09-302012-11-05$N/A-$0.40-$0.20-100%
2012-06-302012-08-02$N/A-$0.40-$0.400%
2012-03-312012-05-10$N/A-$0.49
2011-12-312012-03-26$646000-$0.71
2011-09-302011-11-07$-251000-$0.42
2011-06-302011-08-08$251000-$0.97
2011-03-312011-05-16$395000-$0.71
2010-12-312011-03-28$179000-$0.80
2010-09-302010-11-15$351000-$0.85
2010-06-302010-08-16$530000-$1.81
2010-03-312010-05-18$241000-$0.25
2009-12-312010-03-15$122000-$1.25
2009-09-302009-11-16$1.12 million-$0.78
2009-06-302009-08-04$14000-$2.54
2009-03-312009-05-14$8000-$2.00-$2.000%
2008-12-312009-03-31$21000-$2.60-$4.1036.59%
2008-09-302008-11-05$64000-$4.00-$4.204.76%
2008-06-302008-08-14$151000-$4.00-$4.409.09%
2008-03-312008-05-15$133000-$4.40-$4.30-2.33%
2007-12-312008-03-13$132000-$5.00-$3.50-42.86%
2007-09-302007-11-13$120000-$3.00-$3.000%
2007-06-302007-08-01$160000-$3.80-$12.8070.31%
2007-03-312007-05-08$N/A-$18.93
2006-12-312007-03-07$N/A-$17.60-$11.20-57.14%
2006-09-302006-11-07$N/A-$12.00-$14.4016.67%
2006-06-302006-08-08$N/A-$14.41
2006-03-312006-05-10$N/A$60.59
2005-12-312006-03-15$1.44 million-$8.28
2005-09-302005-11-02$1.34 million-$5.55
2005-06-302005-08-08$1.25 million-$8.31
2005-03-312005-05-10$1.36 million-$4.01
2004-12-312005-03-10$1.48 million-$7.22
2004-09-302004-11-15$1.46 million-$6.05
2004-06-302004-08-12$1.28 million-$9.28
2004-03-312004-04-28$1.18 million-$9.60-$4.80-100%
2003-12-312004-03-12$1.36 million-$5.34
2003-09-302003-11-07$1.27 million-$4.11
2003-06-302003-08-04$1.12 million-$7.52
2003-03-312003-05-05$1.11 million$0.13
2002-09-302002-09-30$1.04 million-$4.12
2002-06-302002-06-30$967000-$5.85
2002-03-312002-03-31$952000-$3.95
2001-09-302001-09-30$969000$5.88
2001-06-302001-06-30$1000000-$4.72
2001-03-312001-03-31$971000-$4.44
2000-09-302000-11-03$887000-$2.40-$4.8050%
2000-06-302000-08-15$869000-$4.00$1.60-350%
2000-03-312000-05-15$730000$0.80
1999-09-301999-11-11$2.40$1.6050%
1999-06-301999-07-29$1.60$4.40-63.64%
1999-03-311999-05-06$1.60$5.60-71.43%
1998-12-311999-03-04$4.80$7.20-33.33%
1998-09-301998-11-04$2.40$4.80-50%
1998-06-301998-07-30$0.80
1998-03-311998-03-31$0.11

Heron Therapeutics, Inc (HRTX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Heron Therapeutics, Inc (HRTX) Chart:

HRTX chart by TradingView

Heron Therapeutics, Inc (HRTX) News:

Below you will find a list of latest news for Heron Therapeutics, Inc (HRTX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Heron Therapeutics, Inc (HRTX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-03-210.51.24CALL0 145295.3TRUE00
2025-03-2110.75CALL0 294239.59TRUE00
2025-03-211.50.3CALL0 362122.09TRUE00
2025-03-2120.09CALL39 167496.46FALSE-0.01-0.1
2025-03-2130.03CALL0 811135.36FALSE00
2025-03-2140.04CALL0 220213.6FALSE00
2025-03-2150.15CALL0 9250.76FALSE00
2025-03-2160.07CALL0 10244.83FALSE00
2025-03-2170CALL0 0528.53FALSE00
2025-03-210.50.15PUT0 56771.47FALSE00
2025-03-2110PUT0 0191.67FALSE00
2025-03-211.50.1PUT10 56112.17FALSE0.10
2025-03-2120.4PUT0 90149.37TRUE00
2025-03-2131.22PUT0 48171.74TRUE00
2025-03-2140PUT0 0285.2TRUE00
2025-03-2153.25PUT0 0327.88TRUE00
2025-03-2160PUT0 0426.34TRUE00
2025-03-2170PUT0 0292.78TRUE00
2025-04-170.50CALL0 0500.31TRUE00
2025-04-1710CALL0 0167.7TRUE00
2025-04-171.50CALL0 061.31TRUE00
2025-04-1720.15CALL13 091.24FALSE0.150
2025-04-1730CALL0 0164.23FALSE00
2025-04-1740CALL0 0345.4FALSE00
2025-04-1750CALL0 0329.7FALSE00
2025-04-170.50PUT0 0767.72FALSE00
2025-04-1710PUT0 0211.28FALSE00
2025-04-171.50PUT0 0102.6FALSE00
2025-04-1720PUT0 030.62TRUE00
2025-04-1730PUT0 0150.53TRUE00
2025-04-1740PUT0 0205.45TRUE00
2025-04-1750PUT0 0175.17TRUE00
2025-06-200.51.26CALL10 173149.98TRUE0.010.01
2025-06-2010.85CALL0 28580.5TRUE00
2025-06-201.50.49CALL0 62055.31TRUE00
2025-06-2020.25CALL0 63986.28FALSE00
2025-06-2030.07CALL50 37984.2FALSE0.070
2025-06-2040.05CALL0 2112.39FALSE00
2025-06-2050.05CALL0 1002131.02FALSE00
2025-06-200.50.15PUT0 40FALSE00
2025-06-2010.14PUT0 3120.18FALSE00
2025-06-201.50.15PUT0 21100.53FALSE00
2025-06-2020.5PUT0 6133.4TRUE00
2025-06-2031.42PUT0 3078.51TRUE00
2025-06-2040PUT0 0117.76TRUE00
2025-06-2050PUT0 0138.95TRUE00
2025-09-190.51.3CALL0 81330.23TRUE00
2025-09-1910.88CALL10 2101.2TRUE0.880
2025-09-191.50.5CALL0 11945.12TRUE00
2025-09-1920.3CALL0 1592.46FALSE00
2025-09-1930.18CALL50 26188.51FALSE0.180
2025-09-1940CALL0 097.45FALSE00
2025-09-1950.06CALL0 20180.81FALSE00
2025-09-190.50PUT0 0159.33FALSE00
2025-09-1910PUT0 091.43FALSE00
2025-09-191.50.35PUT0 171.43FALSE00
2025-09-1920.65PUT0 062.96TRUE00
2025-09-1931.5PUT0 583.41TRUE00
2025-09-1940PUT0 073.39TRUE00
2025-09-1950PUT0 0131.28TRUE00

Latest HRTX Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST100$2.315
Jun 13, 2022 7:59 PM EST75$2.315
Jun 13, 2022 7:59 PM EST9$2.315
Jun 13, 2022 7:59 PM EST100$2.32
Jun 13, 2022 7:59 PM EST74$2.32

Heron Therapeutics, Inc (HRTX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020031058/0001564590-20-031058-index.htm
2018-07-16UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/818033/000000000018021777/0000000000-18-021777-index.htm
2018-08-22UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/818033/000000000018026157/0000000000-18-026157-index.htm
2018-07-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000003877718000193/0000038777-18-000193-index.htm
2019-01-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000003877719000002/0000038777-19-000002-index.htm
2020-02-04SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000003877720000026/0000038777-20-000026-index.htm
2019-02-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000021545719006786/0000215457-19-006786-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000031506619001066/0000315066-19-001066-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000031506620001040/0000315066-20-001040-index.htm
2020-07-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000031506620001651/0000315066-20-001651-index.htm
2020-02-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000083423720005426/0000834237-20-005426-index.htm
2019-02-12SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000090221919000304/0000902219-19-000304-index.htm
2020-01-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000090221920000046/0000902219-20-000046-index.htm
2019-02-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000093247119005421/0000932471-19-005421-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000110465920018119/0001104659-20-018119-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000110465920021753/0001104659-20-021753-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000114420419007225/0001144204-19-007225-index.htm
2018-06-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312518201200/0001193125-18-201200-index.htm
2018-06-258-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312518202464/0001193125-18-202464-index.htm
2018-06-25424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/818033/000119312518202508/0001193125-18-202508-index.htm
2018-06-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/818033/000119312518205702/0001193125-18-205702-index.htm
2018-06-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312518207684/0001193125-18-207684-index.htm
2018-07-30CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/818033/000119312518231460/0001193125-18-231460-index.htm
2018-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312518242059/0001193125-18-242059-index.htm
2018-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/818033/000119312518242064/0001193125-18-242064-index.htm
2018-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312518320928/0001193125-18-320928-index.htm
2018-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/818033/000119312518320941/0001193125-18-320941-index.htm
2018-12-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312518361750/0001193125-18-361750-index.htm
2019-01-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519001151/0001193125-19-001151-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519003247/0001193125-19-003247-index.htm
2019-02-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519028339/0001193125-19-028339-index.htm
2019-02-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519032236/0001193125-19-032236-index.htm
2019-02-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519047774/0001193125-19-047774-index.htm
2019-02-2210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/818033/000119312519047780/0001193125-19-047780-index.htm
2019-02-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519051944/0001193125-19-051944-index.htm
2019-03-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519070125/0001193125-19-070125-index.htm
2019-04-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519093695/0001193125-19-093695-index.htm
2019-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/818033/000119312519122529/0001193125-19-122529-index.htm
2019-04-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/818033/000119312519122544/0001193125-19-122544-index.htm
2019-05-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519130962/0001193125-19-130962-index.htm
2019-05-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519142329/0001193125-19-142329-index.htm
2019-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/818033/000119312519142333/0001193125-19-142333-index.htm
2019-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519146046/0001193125-19-146046-index.htm
2019-05-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519152334/0001193125-19-152334-index.htm
2019-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519176468/0001193125-19-176468-index.htm
2019-07-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519195218/0001193125-19-195218-index.htm
2019-10-03424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/818033/000119312519261632/0001193125-19-261632-index.htm
2019-10-07424B2Prospectus [Rule 424(b)(2)]https://www.sec.gov/Archives/edgar/data/818033/000119312519263773/0001193125-19-263773-index.htm
2019-10-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519264451/0001193125-19-264451-index.htm
2018-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118039348/0001209191-18-039348-index.htm
2018-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118041384/0001209191-18-041384-index.htm
2018-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118041385/0001209191-18-041385-index.htm
2018-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118041386/0001209191-18-041386-index.htm
2018-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118050601/0001209191-18-050601-index.htm
2018-09-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118050997/0001209191-18-050997-index.htm
2018-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118053532/0001209191-18-053532-index.htm
2018-11-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118057056/0001209191-18-057056-index.htm
2018-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118063286/0001209191-18-063286-index.htm
2018-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118063346/0001209191-18-063346-index.htm
2018-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118063347/0001209191-18-063347-index.htm
2018-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118063348/0001209191-18-063348-index.htm
2018-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118063349/0001209191-18-063349-index.htm
2018-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118063350/0001209191-18-063350-index.htm
2018-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118063351/0001209191-18-063351-index.htm
2018-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118063353/0001209191-18-063353-index.htm
2019-02-145Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119010097/0001209191-19-010097-index.htm
2019-05-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119027143/0001209191-19-027143-index.htm
2019-05-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119030201/0001209191-19-030201-index.htm
2019-05-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119032198/0001209191-19-032198-index.htm
2019-07-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119042303/0001209191-19-042303-index.htm
2019-10-013Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119051412/0001209191-19-051412-index.htm
2019-10-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119051413/0001209191-19-051413-index.htm
2019-10-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119052611/0001209191-19-052611-index.htm
2019-10-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119052612/0001209191-19-052612-index.htm
2019-10-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119052702/0001209191-19-052702-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119058834/0001209191-19-058834-index.htm
2019-12-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119061762/0001209191-19-061762-index.htm
2019-12-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119061786/0001209191-19-061786-index.htm
2019-12-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119061788/0001209191-19-061788-index.htm
2019-12-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119061789/0001209191-19-061789-index.htm
2019-12-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119061794/0001209191-19-061794-index.htm
2019-12-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119061795/0001209191-19-061795-index.htm
2019-12-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119061796/0001209191-19-061796-index.htm
2019-12-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119061798/0001209191-19-061798-index.htm
2020-02-145Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919120009590/0001209191-20-009590-index.htm
2020-02-145Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919120009728/0001209191-20-009728-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919120025019/0001209191-20-025019-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919120025021/0001209191-20-025021-index.htm
2020-05-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919120026627/0001209191-20-026627-index.htm
2020-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919120054905/0001209191-20-054905-index.htm
2020-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919120054906/0001209191-20-054906-index.htm
2020-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919120054907/0001209191-20-054907-index.htm
2020-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919120054908/0001209191-20-054908-index.htm
2020-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919120054909/0001209191-20-054909-index.htm
2020-10-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919120054910/0001209191-20-054910-index.htm
2020-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919120054914/0001209191-20-054914-index.htm
2020-10-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919120055390/0001209191-20-055390-index.htm
2018-09-13SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/818033/000121465918006019/0001214659-18-006019-index.htm
2020-01-07SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/818033/000121465920000176/0001214659-20-000176-index.htm
2018-08-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000127417318000093/0001274173-18-000093-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000127417319000052/0001274173-19-000052-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000127417320000028/0001274173-20-000028-index.htm
2019-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459019028536/0001564590-19-028536-index.htm
2019-08-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/818033/000156459019028537/0001564590-19-028537-index.htm
2019-08-05S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/818033/000156459019028818/0001564590-19-028818-index.htm
2019-08-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459019032608/0001564590-19-032608-index.htm
2019-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459019036000/0001564590-19-036000-index.htm
2019-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459019036090/0001564590-19-036090-index.htm
2019-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459019036093/0001564590-19-036093-index.htm
2019-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459019036139/0001564590-19-036139-index.htm
2019-10-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459019037287/0001564590-19-037287-index.htm
2019-10-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459019038027/0001564590-19-038027-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459019042630/0001564590-19-042630-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/818033/000156459019042638/0001564590-19-042638-index.htm
2019-12-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459019045076/0001564590-19-045076-index.htm
2019-12-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459019046060/0001564590-19-046060-index.htm
2019-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459019046547/0001564590-19-046547-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020000917/0001564590-20-000917-index.htm
2020-02-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020005303/0001564590-20-005303-index.htm
2020-03-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020007971/0001564590-20-007971-index.htm
2020-03-0210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/818033/000156459020007973/0001564590-20-007973-index.htm
2020-04-23DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/818033/000156459020018187/0001564590-20-018187-index.htm
2020-04-23DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/818033/000156459020018204/0001564590-20-018204-index.htm
2020-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020021571/0001564590-20-021571-index.htm
2020-05-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/818033/000156459020021575/0001564590-20-021575-index.htm
2020-05-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020025913/0001564590-20-025913-index.htm
2020-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020028307/0001564590-20-028307-index.htm
2020-06-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020029788/0001564590-20-029788-index.htm
2020-06-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020031058/0001564590-20-031058-index.htm
2020-07-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020032445/0001564590-20-032445-index.htm
2020-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020033338/0001564590-20-033338-index.htm
2020-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020036807/0001564590-20-036807-index.htm
2020-08-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/818033/000156459020036822/0001564590-20-036822-index.htm
2020-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020036849/0001564590-20-036849-index.htm
2020-09-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020042727/0001564590-20-042727-index.htm
2020-09-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020043657/0001564590-20-043657-index.htm
2020-09-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020044749/0001564590-20-044749-index.htm
2020-10-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020046256/0001564590-20-046256-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020050909/0001564590-20-050909-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/818033/000156459020050911/0001564590-20-050911-index.htm

Heron Therapeutics, Inc (HRTX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Heron Therapeutics, Inc (HRTX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 29%
Institutional Ownership: 10143%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-07-02KIMBERLY MANHARDExecutive VP, Drug DevelopmentSell100.0038.853,885.000.00https://www.sec.gov/Archives/edgar/data/818033/000120919118041386/0001209191-18-041386-index.htm
2018-10-01KIMBERLY MANHARDExecutive VP, Drug DevelopmentSell6,000.0032.07192,433.200.00https://www.sec.gov/Archives/edgar/data/818033/000120919118053532/0001209191-18-053532-index.htm
2018-11-02KIMBERLY MANHARDExecutive VP, Drug DevelopmentSell494.0030.6215,124.950.00https://www.sec.gov/Archives/edgar/data/818033/000120919118057056/0001209191-18-057056-index.htm
2019-05-01KIMBERLY MANHARDExecutive VP, Drug DevelopmentSell1,109.0018.8620,918.070.00https://www.sec.gov/Archives/edgar/data/818033/000120919119027143/0001209191-19-027143-index.htm
2019-11-29KIMBERLY MANHARDExecutive VP, Drug DevelopmentSell24,000.0026.00624,000.000.00https://www.sec.gov/Archives/edgar/data/818033/000120919119058834/0001209191-19-058834-index.htm
2020-05-01KIMBERLY MANHARDExecutive VP, Drug DevelopmentSell1,158.0013.9716,175.750.00https://www.sec.gov/Archives/edgar/data/818033/000120919120026627/0001209191-20-026627-index.htm
2018-07-02KIMBERLY MANHARDExecutive VP, Drug DevelopmentSell5,900.0037.51221,293.66100.00https://www.sec.gov/Archives/edgar/data/818033/000120919118041386/0001209191-18-041386-index.htm
2018-06-21Barry D QuartChief Executive OfficerBuy50,000.009.05452,500.00119,600.00https://www.sec.gov/Archives/edgar/data/818033/000120919118039348/0001209191-18-039348-index.htm
2018-07-02ROBERT HOFFMANCFO & SVP, FinanceSell1,060.0038.8041,123.021,280.00https://www.sec.gov/Archives/edgar/data/818033/000120919118041385/0001209191-18-041385-index.htm
2019-05-22JOHN POYHONENDirectorBuy3,000.0017.5552,650.0013,000.00https://www.sec.gov/Archives/edgar/data/818033/000120919119032198/0001209191-19-032198-index.htm
2018-06-29Robert RosenPresidentBuy129,469.007.20932,176.80132,109.00https://www.sec.gov/Archives/edgar/data/818033/000120919118041384/0001209191-18-041384-index.htm
2019-05-15Waage ChristianDirectorBuy1,400.0018.0425,261.741,400.00https://www.sec.gov/Archives/edgar/data/818033/000120919119030201/0001209191-19-030201-index.htm
2019-10-03JOHN POYHONENEVP, Chief Commercial OfficerBuy5,143.0017.5090,002.5018,143.00https://www.sec.gov/Archives/edgar/data/818033/000120919119052611/0001209191-19-052611-index.htm
2018-07-02ROBERT HOFFMANCFO & SVP, FinanceSell28,940.0038.151,104,107.302,340.00https://www.sec.gov/Archives/edgar/data/818033/000120919118041385/0001209191-18-041385-index.htm
2019-11-29KIMBERLY MANHARDExecutive VP, Drug DevelopmentBuy24,000.0013.00312,000.0024,000.00https://www.sec.gov/Archives/edgar/data/818033/000120919119058834/0001209191-19-058834-index.htm
2018-06-29Robert RosenPresidentSell2,112.0041.3987,415.472,640.00https://www.sec.gov/Archives/edgar/data/818033/000120919118041384/0001209191-18-041384-index.htm
2018-07-02Robert RosenPresidentSell3,400.0038.75131,764.962,640.00https://www.sec.gov/Archives/edgar/data/818033/000120919118041384/0001209191-18-041384-index.htm
2018-07-02ROBERT HOFFMANCFO & SVP, FinanceBuy30,000.0015.30459,000.0031,280.00https://www.sec.gov/Archives/edgar/data/818033/000120919118041385/0001209191-18-041385-index.htm
2018-06-29Robert RosenPresidentSell51,696.0040.172,076,597.304,752.00https://www.sec.gov/Archives/edgar/data/818033/000120919118041384/0001209191-18-041384-index.htm
2018-06-29Robert RosenPresidentSell75,661.0039.142,961,121.8656,448.00https://www.sec.gov/Archives/edgar/data/818033/000120919118041384/0001209191-18-041384-index.htm
2019-10-04KEVIN C TANGDirectorBuy285,714.0017.504,999,995.005,799,810.00https://www.sec.gov/Archives/edgar/data/818033/000120919119052702/0001209191-19-052702-index.htm
2018-09-12KEVIN C TANGDirectorSell2,695,000.0035.7596,346,250.005,830,215.00https://www.sec.gov/Archives/edgar/data/818033/000120919118050601/0001209191-18-050601-index.htm
2018-07-02KIMBERLY MANHARDExecutive VP, Drug DevelopmentBuy6,000.0013.0078,000.006,000.00https://www.sec.gov/Archives/edgar/data/818033/000120919118041386/0001209191-18-041386-index.htm
2018-10-01KIMBERLY MANHARDExecutive VP, Drug DevelopmentBuy6,000.0013.0078,000.006,000.00https://www.sec.gov/Archives/edgar/data/818033/000120919118053532/0001209191-18-053532-index.htm
2018-07-02Robert RosenPresidentSell92,131.0038.133,512,918.186,040.00https://www.sec.gov/Archives/edgar/data/818033/000120919118041384/0001209191-18-041384-index.htm
2018-06-21Barry D QuartChief Executive OfficerSell50,000.0039.051,952,500.0069,600.00https://www.sec.gov/Archives/edgar/data/818033/000120919118039348/0001209191-18-039348-index.htm
2018-09-14Barry D QuartChief Executive OfficerBuy19,675.007.20141,660.0089,275.00https://www.sec.gov/Archives/edgar/data/818033/000120919118050997/0001209191-18-050997-index.htm
2019-10-03Barry D QuartChief Executive OfficerBuy4,571.0017.5079,992.5094,652.00https://www.sec.gov/Archives/edgar/data/818033/000120919119052612/0001209191-19-052612-index.htm
2018-07-02Robert RosenPresidentBuy95,531.007.20687,823.2098,171.00https://www.sec.gov/Archives/edgar/data/818033/000120919118041384/0001209191-18-041384-index.htm